Helus Pharma (NASDAQ: HELP) (Cboe CA: HELP) announced that CEO Michael Halstead will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference in New York City. The session is scheduled for Sept. 16 at 8:30 a.m. EDT and will be webcast live, with a replay available on the Events & Presentations page of Helus Pharma's investor relations website. The full press release can be viewed at https://ibn.fm/r0jfC.
The appearance at a major healthcare investor conference matters because it gives Helus Pharma a platform to update the investment community on its pipeline of proprietary novel serotonergic agonists, or NSAs. These synthetic molecules are designed to activate serotonin pathways that are believed to promote neuroplasticity. The company is targeting a large unmet need among people who suffer from depression, anxiety, and other mental health conditions.
Helus Pharma, the commercial operating name of Cybin Inc., was founded in 2019 and is a clinical-stage pharmaceutical company committed to helping minds heal. Its lead program, HLP003, is in Phase 3 clinical development for the adjunctive treatment of major depressive disorder and has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration. A second program, HLP004, is in Phase 2 for generalized anxiety disorder. The company also maintains an extensive research portfolio of investigational NSAs.
With class-leading data, Helus Pharma aims to improve the treatment landscape by introducing NSAs that may provide durable improvements in mental health. That goal is significant for patients and providers because depression and anxiety remain widespread and often inadequately treated. If the company's NSAs succeed in later-stage trials, they could offer new options for conditions where current therapies do not work well for everyone.
For investors, the Morgan Stanley conference provides a chance to hear directly from management about clinical progress and strategy. The webcast and replay make the discussion accessible to a broad audience, which can help keep the market informed about Helus Pharma's milestones. The company operates in Canada, the United States, the United Kingdom, and Ireland.
Helus Pharma encourages investors and other interested parties to visit its website at www.helus.com for company updates and to learn more. The latest news and updates relating to HELP are available in the company's newsroom at https://ibn.fm/HELP. Helus Pharma is a trademark of Cybin Corp.
